Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

393
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
393
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.9K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.9K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

518
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
518
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

373
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
373
Prevalence and Incidence01:08

Prevalence and Incidence

2.5K
In statistical epidemiology and health sciences, two essential metrics—prevalence and incidence—are fundamental for understanding disease dynamics within a population. These measures enable public health officials, epidemiologists, and researchers to assess the burden of diseases, allocate resources effectively, and design impactful public health policies and interventions.
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
2.5K
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

944
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
944

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Drivers of Vertical HIV Transmission in Sub-Saharan Africa and the Impact and Cost-Effectiveness of Targeted and Universal Lenacapavir Pre-Exposure Prophylaxis.

Journal of the International AIDS Society·2026
Same author

The impact of US Government Stop Work Order on HIV epidemic trajectory in Zimbabwe.

PLOS global public health·2026
Same author

Low-Barrier Fibrosis Screening in Hepatitis C Treatment: The Decompensated Cirrhosis in Hepatitis C Evaluation Questionnaire.

Journal of viral hepatitis·2026
Same author

The benefits of investments to combat HIV, tuberculosis, and malaria for primary healthcare from 2000 to 2023: An economic modeling analysis.

PLoS medicine·2026
Same author

Effectiveness and safety of darunavir and lopinavir for treating children and adolescents living with HIV: a systematic review.

BMC infectious diseases·2026
Same author

Impact of Thrombolytic Treatment on Functional Rehabilitation in Severe Frostbite Patients.

Journal of burn care & research : official publication of the American Burn Association·2026

Related Experiment Video

Updated: Apr 20, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.4K

Estimating future trends in paediatric HIV.

Martina Penazzato1, Victoria Bendaud, Lisa Nelson

  • 1aHIV Department, WHO bProgramme Branch, UNAIDS, Geneva, Switzerland cFutures institute, Glastonbury, CT, USA.

AIDS (London, England)
|November 20, 2014
PubMed
Summary
This summary is machine-generated.

Antiretroviral therapy (ART) scale-up is crucial for children living with HIV. By 2020, significant numbers of children will still require age-appropriate ART, highlighting the need for improved drug development and forecasting.

More Related Videos

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.5K
Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

13.8K

Related Experiment Videos

Last Updated: Apr 20, 2026

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.4K
An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.5K
Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach
07:06

Prediction of HIV-1 Coreceptor Usage Tropism by Sequence Analysis using a Genotypic Approach

Published on: December 1, 2011

13.8K

Area of Science:

  • Public Health
  • Epidemiology
  • Pediatric Infectious Diseases

Background:

  • Paediatric treatment for HIV lags behind adult care, necessitating urgent scaling of antiretroviral therapy (ART).
  • Expanding mother-to-child HIV transmission prevention requires better understanding of future paediatric ART needs.
  • Policymakers, drug developers, and manufacturers need updated projections for paediatric HIV care.

Purpose of the Study:

  • To estimate the number of children requiring ART in 21 African priority countries by 2020.
  • To analyze different ART scale-up scenarios and their impact on paediatric HIV.
  • To characterize the age distribution of children needing ART.

Main Methods:

  • Utilized the Spectrum model to project paediatric HIV infections and ART needs.
  • Investigated various ART scale-up scenarios for children in high-burden African countries.
  • Explored age-specific trends in the paediatric population requiring ART.

Main Results:

  • New paediatric HIV infections are projected to decline by 2020 across all scenarios.
  • Total paediatric HIV infections will decrease, with variations by scenario and age group.
  • Under optimal scale-up, approximately 1,940,000 children will be living with HIV in 2020, with 1,670,000 requiring ART.

Conclusions:

  • A substantial number of children will remain HIV-positive by 2020, even with optimistic ART scale-up.
  • Development of age-appropriate paediatric ART drugs and formulations is essential.
  • Enhanced epidemiological estimates are critical for guiding paediatric treatment commodity development and closing the treatment gap.